Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multiple Dose, Placebo-Controlled Trial to Determine the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of ALD403, a Humanized Anti-(Calcitonin Gene-Related Peptide) Monoclonal Antibody in Healthy Volunteers

Next Previous
Search
Trial Profile

A Multiple Dose, Placebo-Controlled Trial to Determine the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of ALD403, a Humanized Anti-(Calcitonin Gene-Related Peptide) Monoclonal Antibody in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Oct 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eptinezumab (Primary) ; Eptinezumab (Primary) ; Eptinezumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions
  • Sponsors Alder Biopharmaceuticals

    • Most Recent Events

    • 15 Sep 2016 According to an Alder Biopharmaceuticals media release, results from this trial presented at the 5th European Headache and Migraine Trust International Congress (EHMTIC 2016).
    • 15 Sep 2016 Results published in an Alder Biopharmaceuticals Media Release
    • 08 Sep 2016 According to an Alder Biopharmaceuticals media release, results from this trial will be presented at the 5th European Headache and Migraine Trust International Congress (EHMTIC 2016).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top